Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | ACP3 | P15309 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164290 | 1.00 | CA4 (0.58) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL2601110 | 0.91 | CA1 (0.55) | CA4PBRM1LTA4HALDH1A1CA12 | |
| SCHEMBL8429413 | 0.89 | PBRM1 (0.62) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL5941221 | 0.89 | PBRM1 (0.62) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL8323074 | 0.84 | PBRM1 (0.54) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL15617631 | 0.84 | ACP3 (0.56) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL10442181 | 0.83 | ACHE (0.62) | CA4PBRM1ALDH1A1CA12CA1 | |
| SCHEMBL15849969 | 0.83 | ALDH1A1 (0.58) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL156425 | 0.83 | ALDH1A1 (0.58) | CA4PBRM1LTA4HACP3ALDH1A1 | |
| SCHEMBL15586 | 0.82 | TAAR1 (0.48) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100022637-A1 | IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | CA4 1416/4885PBRM1 4665/4885LTA4H 688/4885 |
| US-20100022637-A1 | IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF | HTT, ATXN2, HDAC6 | CA4 4560/4885PBRM1 3815/4885LTA4H 2223/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | CA4 2161/4885PBRM1 4565/4885LTA4H 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.